Big data in pharmacogenomics: current applications, perspectives and pitfalls.

Abstract:

:The efficiency of new generation sequencing methods and the reduction of their cost has led pharmacogenomics to gradually supplant pharmacogenetics, leading to new applications in personalized medicine along with new perspectives in drug design or identification of drug response factors. The amount of data generated in genomics fits the definition of big data, and need a specific bioinformatics processing following standard steps: data collection, processing, analysis and interpretation. Pitfalls of pharmacogenomics studies are directly related to these steps. This review aims to describe these steps from a pharmacogenomic point of view, focusing on bioinformatics aspects.

journal_name

Pharmacogenomics

journal_title

Pharmacogenomics

authors

Barrot CC,Woillard JB,Picard N

doi

10.2217/pgs-2018-0184

subject

Has Abstract

pub_date

2019-06-01 00:00:00

pages

609-620

issue

8

eissn

1462-2416

issn

1744-8042

journal_volume

20

pub_type

杂志文章
  • Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study.

    abstract::The successful application of pharmacogenetics in routine clinical practice is still a long way from becoming a reality. In order to favor the transfer of pharmacogenetic results to clinical practice, especially in psychiatry, these studies must be optimized. This article reviews the strengths and weaknesses that char...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,多中心研究,评审

    doi:10.2217/pgs.12.159

    authors: Mas S,Llerena A,Saíz J,Bernardo M,Lafuente A

    更新日期:2012-11-01 00:00:00

  • Parkinson's disease pharmacogenomics: new findings and perspectives.

    abstract::Parkinson's disease (PD) is unique among neurodegenerative disorders because a highly effective pharmacological symptomatic treatment is available. The marked variability in drug response and in adverse profiles associated with this treatment led to the search of genetic markers associated with these features. We pres...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.14.93

    authors: Schumacher-Schuh AF,Rieder CR,Hutz MH

    更新日期:2014-06-01 00:00:00

  • High-throughput genotyping assay approaches.

    abstract::High-throughput genotyping approaches are being developed to meet the demands of pharmacogenomnics, where numerous individuals are studied with thousands of single nucleotide polymorphism (SNP) markers. All non-gel-based genotyping approaches achieve allelic discrimination by one of four mechanisms: allele-specific hy...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.1.1.95

    authors: Kwok PY

    更新日期:2000-02-01 00:00:00

  • Challenges for molecular profiling of chronic fatigue syndrome.

    abstract::Chronic fatigue syndrome (CFS) is prevalent, disabling and costly. Despite extensive literature describing the epidemiology and clinical aspects of CFS, it has been recalcitrant to diagnostic biomarker discovery and therapeutic intervention. This is due to the fact that CFS is a complex illness defined by self-reporte...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.7.2.211

    authors: Vernon SD,Whistler T,Aslakson E,Rajeevan M,Reeves WC

    更新日期:2006-03-01 00:00:00

  • 677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis.

    abstract:INTRODUCTION:Methotrexate (MTX), widely used in the treatment of rheumatoid arthritis (RA), inhibits dihydrofolate reductase and folate-dependent enzymes. Methylenetetrahydrofolate reductase (MTHFR) is involved in folate metabolism and has been shown to be polymorphic, affecting the enzyme activity. METHODS:To examine...

    journal_title:Pharmacogenomics

    pub_type: 临床试验,杂志文章

    doi:10.2217/14622416.8.11.1551

    authors: Kurzawski M,Pawlik A,Safranow K,Herczynska M,Drozdzik M

    更新日期:2007-11-01 00:00:00

  • Codeine-induced acute generalized exanthematous pustulosis without IL36RN mutations.

    abstract::Recent studies have suggested an association between mutations in the IL-36RN gene and the onset of pustular generalized. In the literature, only one case of acute generalized exanthematous pustulosis (AGEP) induced by codeine in a patient with IL36RN mutation has been reported. Herein, we reported an unusual case of ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2017-0200

    authors: Chadli Z,Ladhari C,Kerkeni E,Djobbi A,Fredj NB,Chaabane A,Boughattas NA,Aouam K

    更新日期:2018-07-01 00:00:00

  • microRNA expression changes after atrial fibrillation catheter ablation.

    abstract::Atrial fibrillation (AF) is most common arrhythmia in general population, with increasing trend in mortality and morbidity. Electrophysiological and structural abnormalities, promoting abnormal impulse formation and propagation, lead to this disease. AF catheter ablation is related to a not small percentage of nonresp...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.15.117

    authors: Sardu C,Santamaria M,Paolisso G,Marfella R

    更新日期:2015-11-01 00:00:00

  • Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer.

    abstract::Recent advances in next-generation sequencing techniques have greatly improved our understanding of the genomic alterations in bladder cancer. Cisplatin-based chemotherapy provides a viable treatment option in the neoadjuvant, adjuvant and metastatic setting in a selected group of patients, but chemoresistance is a ma...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2017-0055

    authors: Zuiverloon TC,Theodorescu D

    更新日期:2017-08-01 00:00:00

  • Copy number variation and gene rearrangements in CYP2D6 genotyping using multiplex ligation-dependent probe amplification in Koreans.

    abstract:AIM:The present study introduces a simple method for CYP2D6 genotyping that not only determines the heterozygous or homozygous deletions and duplications, but also distinguishes tandem hybrids. MATERIALS & METHODS:Using two commercially available methods, 49 Korean male subjects were genotyped for CYP2D6. The Affymetr...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.12.58

    authors: Kim J,Lee SY,Lee KA

    更新日期:2012-06-01 00:00:00

  • Pharmacogenomics of beta2-agonist: key focus on signaling pathways.

    abstract::Asthma is one of the most common respiratory diseases, where inhalation and exhalation are obstructed due to narrowing of the airways by broncho-constriction or by inflammation. Among all the available anti-asthma therapies, beta2-agonists are the most effective bronchodilators available, and give rapid relief of asth...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.7.6.919

    authors: Bhatnagar P,Guleria R,Kukreti R

    更新日期:2006-09-01 00:00:00

  • The pharmacogenetics of NAT: structural aspects.

    abstract::Arylamine N-acetyltransferases (NATs) catalyze the transfer of an acetyl group from acetyl-CoA to arylhydrazines and to arylamine drugs and carcinogens or to their N-hydroxylated metabolites. NAT plays an important role in detoxification and metabolic activation of xenobiotics and was first identified as the enzyme re...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.3.1.19

    authors: Pompeo F,Brooke E,Kawamura A,Mushtaq A,Sim E

    更新日期:2002-01-01 00:00:00

  • The changing field of vaccine development in the genomics era.

    abstract::An improved understanding of the human immune system and the genetic make-up of pathogens, together with advances in instrumentation and bioinformatics, have provided new insights into the variation of immune responses to vaccines within the human population. Pathogen variation and the diversity of the immune system c...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.1517/14622416.5.6.597

    authors: Brusic V,August JT

    更新日期:2004-09-01 00:00:00

  • Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.

    abstract:AIM:Our objective was to describe the association between voriconazole concentrations and CYP2C19 diplotypes in pediatric cancer patients, including children homozygous for the CYP2C19*17 gain-of-function allele. MATERIALS & METHODS:A linear mixed effect model compared voriconazole dose-corrected trough concentrations...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.14.53

    authors: Hicks JK,Crews KR,Flynn P,Haidar CE,Daniels CC,Yang W,Panetta JC,Pei D,Scott JR,Molinelli AR,Broeckel U,Bhojwani D,Evans WE,Relling MV

    更新日期:2014-06-01 00:00:00

  • Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes.

    abstract:AIMS:To study the frequency distribution of cytochrome P450 (CYP) functional genetic variants in five Eurasian populations from the territory of Siberia in Russia. MATERIALS & METHODS:Unrelated healthy Tuvinians, Buryats, Altaians, Yakuts and Russians (n = 87-88) were genotyped for CYP2C9*2, CYP2C9*3, CYP2C19*2, CYP2C...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.9.7.847

    authors: Makeeva O,Stepanov V,Puzyrev V,Goldstein DB,Grossman I

    更新日期:2008-07-01 00:00:00

  • Epigenetics of cancer progression.

    abstract::Alteration in epigenetic regulation of gene expression is a frequent event in human cancer. CpG island hypermethylation and downregulation is observed for many genes involved in a diverse range of functions and pathways that become deregulated in cancer. Paradoxically, global hypomethylation is a hallmark of almost al...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.9.2.215

    authors: Vucic EA,Brown CJ,Lam WL

    更新日期:2008-02-01 00:00:00

  • Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review.

    abstract:AIM:To determine diagnostic accuracy of HLA-B*57:01 testing for prediction of abacavir-induced hypersensitivity and to quantify the clinical benefit of pretreatment screening through a meta-analytic review of published studies. METHODS:A comprehensive search was performed up to June 2013. The methodological quality of...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,meta分析

    doi:10.2217/pgs.14.52

    authors: Cargnin S,Jommi C,Canonico PL,Genazzani AA,Terrazzino S

    更新日期:2014-05-01 00:00:00

  • Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations.

    abstract::Recently, the USA FDA has made a labeling change to the drug information contained in carbamazepine. Owing to recent data implicating the HLA allele B*1502 as a marker for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese, the FDA recommends genotyping all Asians for the alle...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.9.10.1543

    authors: Ferrell PB Jr,McLeod HL

    更新日期:2008-10-01 00:00:00

  • Murine pharmacogenomics: using the mouse to understand the genetics of drug therapy.

    abstract::Pharmacogenomics seeks to understand the genetic basis of interindividual differences in drug disposition and effects. Differential drug response is likely to most often be a complex trait, in which multiple genes contribute with varying strengths to the therapeutic phenotype. Due to technical and economic limitations...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.3.6.781

    authors: Watters JW,McLeod HL

    更新日期:2002-11-01 00:00:00

  • Gene expression profiling to monitor therapeutic and adverse effects of antisense therapies for Duchenne muscular dystrophy.

    abstract:OBJECTIVES:The objective of this study was to assess the utility of the gene expression profiling technique for the preclinical evaluation of drug efficacy and safety, taking a new therapeutic approach for Duchenne muscular dystrophy (DMD) as an example. METHODS:Muscles from dystrophin-deficient (mdx) mice, a well-cha...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.7.3.281

    authors: 't Hoen PA,van der Wees CG,Aartsma-Rus A,Turk R,Goyenvalle A,Danos O,Garcia L,van Ommen GJ,den Dunnen JT,van Deutekom JC

    更新日期:2006-04-01 00:00:00

  • Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan.

    abstract:OBJECTIVE:We designed this trial to investigate if modifications in levels of circulating vascular endothelial growth factor (VEGF) may be related to clinical response and outcome in advanced colorectal cancer patients during treatment with a weekly combination of cetuximab plus irinotecan. METHODS:A total of 45 heavi...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.8.4.319

    authors: Vincenzi B,Santini D,Russo A,Gavasci M,Battistoni F,Dicuonzo G,Rocci L,Rosaria VM,Gebbia N,Tonini G

    更新日期:2007-04-01 00:00:00

  • Relationship between mRNA expression levels of CYP3A4, CYP3A5 and SXR in peripheral mononuclear blood cells and aging in young kidney transplant recipients under tacrolimus treatment.

    abstract:AIM:The activity of several key enzymes involved in the metabolism of many drugs is subject to change closely related to the age of patients. This possibility must also be considered in the case of tacrolimus, the most important calcineurins inhibitor, which is widely used in pediatric kidney transplantation. As well a...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.15.18

    authors: Ferraresso M,Turolo S,Belingheri M,Tirelli AS,Cortinovis I,Milani S,Edefonti A,Ghio L

    更新日期:2015-01-01 00:00:00

  • Pharmacogenovigilance: a pharmacogenomics pharmacovigilance program.

    abstract::In this report, we review the importance of pharmacovigilance in detecting postmarketing adverse drug events and the potential for developing pharmacogenovigilance programs by integrating pharmacogenomics with pharmacovigilance. We propose to start developing such a program in primary healthcare systems that use basic...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.14.44

    authors: Awada Z,Zgheib NK

    更新日期:2014-04-01 00:00:00

  • Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip.

    abstract::Human cytochrome P450 (CYP)3A is a major P450 enzyme found in the liver and gastrointestinal tract. It plays an important role in the metabolism of a wide variety of drugs, some endogenous steroids and harmful environmental contaminants. It has been shown that CYP3A alleles encoding enzymes with little or no activity ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.6.7.731

    authors: Liu CH,Peck K,Huang JD,Lin MS,Wang CH,Hsu WP,Wang HW,Lee HL,Lai ML

    更新日期:2005-10-01 00:00:00

  • ALK gene alterations in cancer: biological aspects and therapeutic implications.

    abstract::ALK was first reported in 1994 as a translocation in anaplastic large cell lymphoma and then described with different abnormalities in a number of tumors. Recently, a shortly accumulated biomedical research clarified the numerous biological processes underlying its ability to support cancer development, growth and pro...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2016-0166

    authors: Palmirotta R,Quaresmini D,Lovero D,Silvestris F

    更新日期:2017-02-01 00:00:00

  • Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population.

    abstract::The extent of genetic variation found in drug metabolism genes and its contribution to interindividual variation in response to medication remains incompletely understood. To better determine the identity and frequency of variation in 11 phase I drug metabolism genes, the exons and flanking intronic regions of the cyt...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.1517/14622416.5.7.895

    authors: Solus JF,Arietta BJ,Harris JR,Sexton DP,Steward JQ,McMunn C,Ihrie P,Mehall JM,Edwards TL,Dawson EP

    更新日期:2004-10-01 00:00:00

  • Epilepsy pharmacogenetics.

    abstract::Large interindividual variation in efficacy and adverse effects of anti-epileptic therapy presents opportunities and challenges in pharmacogenomics. Although the first true association of genetic polymorphism in drug-metabolizing enzymes with anti-epileptic drug dose was reported 10 years ago, most of the findings hav...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.09.34

    authors: Kasperaviciūte D,Sisodiya SM

    更新日期:2009-05-01 00:00:00

  • Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder.

    abstract:AIMS:Bipolar disorder (BD) is a lifelong psychiatric illness characterized by manic and depressive episodes affecting 1-5% of the general population. Among mood-stabilizing treatments, lithium represents the mainstay in the therapeutic management of BD. However, besides the relatively high rate of excellent responders,...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.11.102

    authors: Squassina A,Manchia M,Borg J,Congiu D,Costa M,Georgitsi M,Chillotti C,Ardau R,Mitropoulos K,Severino G,Del Zompo M,Patrinos GP

    更新日期:2011-11-01 00:00:00

  • miRNAs: from neurogeneration to neurodegeneration.

    abstract::miRNAs are reported to sequence-specifically control the translation of target mRNAs by binding to 3 UTRs. The abundant expression of miRNAs in the brain highlights their biological significance in neurodevelopment. Many studies have shown that miRNAs are involved in a variety of functions, including developmental tra...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.8.8.971

    authors: Singh SK

    更新日期:2007-08-01 00:00:00

  • Discovery Partners International.

    abstract::Discovery Partners International (Nasdaq: DPII) is a leader in collaborative drug discovery. DPI's integrated discovery framework encompasses a broad spectrum of capabilities in chemistry, biology, informatics, computational modeling and synthesis automation. DPI's approach to drug discovery places a heavy emphasis on...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.1517/14622416.3.1.145

    authors: Herd C

    更新日期:2002-01-01 00:00:00

  • Epigenetic and pharmacoepigenomic studies of major psychoses and potentials for therapeutics.

    abstract::Individuals with neuropsychiatric diseases have epigenetic programming disturbances, both in the brain, which is the primary affected organ, and in secondary tissues. Epigenetic modulations are molecular modifications made to DNA, RNA and proteins that fine-tune genotype into phenotype and do not include DNA base chan...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.9.12.1809

    authors: Abdolmaleky HM,Zhou JR,Thiagalingam S,Smith CL

    更新日期:2008-12-01 00:00:00